USP19

Across TCGA pan-cancer cohorts, USP19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated USP19 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher USP19 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated USP19 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where USP19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.768	0.470	.015	13	view →
GBM	OS	Tertile	All	0.622	0.899	.009	12	view →
LUAD	DFS	Median	II,III,IV	1.000	0.798	.015	12	view →
PDAC	OS	Tertile	II,III,IV	0.959	0.760	.015	8	view →
HNSC	DFS	Median	IV	1.000	0.924	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

USP19–CCRCC (DFS)

Open the CCRCC breakdown →